GlassScriptPhysician profile
Manisha Chandar
NPI 1265873566
$22,955.72
in general payments reported to CMS, 2019-2025
59 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $2,540 · 2021: $5,011 · 2022: $2,132 · 2023: $3,244 · 2024: $6,981 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,556 · Food and Beverage: $5,310 · Long Term Medical Supply Or Device Loan: $299 · Education: $17.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,556.25 |
| Food and Beverage | $5,309.92 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $17.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $3,922.61 | 2020-2024 | Xpovio |
| Daiichi Sankyo INC. | $3,343.28 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals LP | $3,063.99 | 2019-2025 | Enhertu, Lynparza |
| Seagen INC. | $2,842.40 | 2020-2023 | Tukysa, Adcetris |
| Novartis Pharmaceuticals Corporation | $1,495.93 | 2019-2025 | |
| Celgene Corporation | $840.75 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $662.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $551.36 | 2019-2025 | Keytruda, Keytruda Qlex |
| Astellas Pharma US INC | $387.09 | 2019-2025 | Xospata, Padcev, Vyloy |
| Abbvie INC. | $380.72 | 2020-2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $346.81 | 2020-2023 | Imbruvica |
| Amgen INC. | $317.42 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Rigel Pharmaceuticals, INC. | $298.13 | 2019-2024 | Rezlidhia, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $288.78 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $274.41 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $257.74 | 2021-2025 | Darzalex, Carvykti, Erleada |
| Caris Mpi, INC. | $237.20 | 2025 | Mi Cancer Seek |
| Genzyme Corporation | $231.10 | 2021-2024 | |
| Genentech USA, INC. | $218.87 | 2019-2025 | Polivy, Tecentriq, Alecensa |
| Genmab U.S., INC. | $210.04 | 2023-2025 | Epkinly, Tivdak |
| Lilly USA, LLC | $197.61 | 2019-2025 | Verzenio, Jaypirca |
| Alexion Pharmaceuticals, INC. | $189.87 | 2019-2023 | Ultomiris |
| Array Biopharma INC | $179.44 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $164.47 | 2021-2023 | Fruzaqla |
| Gilead Sciences, INC. | $156.38 | 2021-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $155.19 | 2020-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $154.03 | 2019-2025 | |
| Eisai INC. | $153.76 | 2020-2024 | |
| Kite Pharma, INC. | $127.21 | 2022-2025 | Yescarta |
| Mirati Therapeutics, INC. | $105.76 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $102.34 | 2020-2023 | |
| Ipsen Biopharmaceuticals, INC | $100.89 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $82.79 | 2020-2021 | |
| Beigene USA, INC. | $71.47 | 2024-2025 | Brukinsa, Tevimbra |
| Sun Pharmaceutical Industries INC. | $64.44 | 2020-2024 | Yonsa, Odomzo |
| Glaxosmithkline, LLC. | $62.49 | 2021-2024 | Ojjaara |
| Springworks Therapeutics, INC. | $62.31 | 2024-2025 | Ogsiveo |
| Beone Medicines USA, INC. | $62.06 | 2025 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $60.71 | 2022-2024 | Fotivda |
| Emd Serono, INC. | $53.16 | 2023-2024 | Bavencio, Tepmetko |
| Epizyme, INC. | $39.30 | 2020-2021 | |
| Iovance Biotherapeutics, INC. | $37.47 | 2025 | Amtagvi |
| Blueprint Medicines Corporation | $35.81 | 2021-2023 | Ayvakit |
| Tersera Therapeutics LLC | $35.09 | 2025 | Zoladex |
| Tg Therapeutics, INC. | $34.65 | 2021 | |
| Deciphera Pharmaceuticals INC. | $31.11 | 2025 | Qinlock, Romvimza |
| Exelixis INC. | $28.25 | 2024 | Cabometyx |
| Adaptive Biotechnologies Corporation | $28.19 | 2023 | Clonoseq |
| Pharmaessentia USA Corporation | $24.69 | 2025 | Besremi |
| Immunomedics, INC. | $21.94 | 2020 | |
| Sobi, INC | $21.11 | 2023 | |
| Recordati_rare_diseases_inc. | $20.49 | 2025 | Enjaymo |
| Myovant Sciences INC. | $19.21 | 2022 | |
| Legend Biotech USA INC. | $18.26 | 2025 | Carvykti |
| Kyowa Kirin, INC. | $17.88 | 2023 | Poteligeo |
| Pharmacosmos Therapeutics INC. | $17.87 | 2025 | Monoferric |
| Servier Pharmaceuticals LLC | $16.68 | 2021 | |
| Myriad Genetic Laboratories, INC. | $15.31 | 2025 | Precisetumor |
| Mylan Institutional INC. | $15.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Chandar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.